IBX.AU · Imagion Biosystems Limited

-

Please sign in to comment on IBX.AU

1 Comment

Admin

4 years, 1 month ago

Imagion Biosystems Limited is currently in a long term downtrend where the price is trading 32.0% below its 200 day moving average.

From a valuation standpoint, the stock is 111.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 544.7.

Imagion Biosystems Limited's total revenue rose by 191.1% to $384K since the same quarter in the previous year.

Its net income has dropped by 48.2% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 204.6% to $-2M since the same quarter in the previous year.

Based on the above factors, Imagion Biosystems Limited gets an overall score of 1/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU000000IBX6
Sector	Healthcare
Industry	Diagnostics & Research

Market Cap	2M
PE Ratio	None
Target Price	None
Beta	1.59
Dividend Yield	None

ABOUT

Imagion Biosystems Limited

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.

IBX.AU · Imagion Biosystems Limited

-

Imagion Biosystems Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Imagion Biosystems Limited using a moving average strategy